Antibiotic resistance (AMR) has officially entered the global pandemic conversation. For the first time, the world's newly adopted pandemic agreement includes antimicrobial resistance as a critical health threatâa landmark decision that reflects how seriously experts now view drug-resistant infections. The stakes are enormous: resistance causes an estimated 4.95 million deaths annually and drives healthcare costs up to 25% in low-income countries, according to new research examining the implications of this inclusion. This shift marks a turning point in how the world addresses infectious disease threats. Traditionally, pandemic planning focused on viruses like COVID-19, flu, and RSV. But antimicrobial resistance operates differentlyâit's a slow-moving crisis that affects bacteria, not just viruses, and it touches every corner of healthcare, agriculture, and animal health. The World Bank projects that if left unchecked, AMR could reduce global GDP by 3.8% by 2050, with low- and middle-income countries facing the most severe consequences. What Does It Mean to Include Antibiotic Resistance in a Pandemic Agreement? The newly finalized pandemic agreement, completed in May 2025, establishes a framework for international collaboration on infectious disease threats. By including AMR, countries are committing to coordinate efforts on surveillance, research, and access to new antibioticsâmuch like they would for a viral pandemic. However, experts emphasize that the real work lies ahead in implementation. The agreement outlines several key commitments, including sustainable national financing and support for developing National Action Plans on antimicrobial resistance. The United Nations allocated $100 million to help at least 60% of countries create and fund these plans by 2030. Additionally, the UN General Assembly made 62 recommendations and 45 commitments in 2024 aimed at reducing deaths from bacterial resistance by 10% by 2030. Why Is This So Urgent Right Now? The urgency stems from a troubling reality: antibiotic development is not keeping pace with the emergence of drug-resistant bacteria. The World Health Organization (WHO) recently released blueprints for three new types of antibiotics that are desperately needed, targeting infections that are becoming increasingly difficult to treat. These include severe infections caused by carbapenem-resistant bacteria, antibiotic-resistant gram-positive infections in critically ill patients, and bacterial meningitis. "We need a reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need them," explained Dr. Yvan Hutin, director of antimicrobial resistance at the WHO. The challenge is clear: while some new antibiotics have been developed in recent years, they are insufficient to match the speed at which bacteria are evolving resistance. Steps to Strengthen Global Response to Antibiotic Resistance - Governance Frameworks: Countries must strengthen legal structures and coordination mechanisms at the national level to detect, monitor, and respond to resistant infections, similar to how they track viral pandemics. - Equitable Access: Ensuring that new antibiotics are affordable and accessible to low- and middle-income countries, where the burden of resistance is greatest, requires sustained international financing and technology transfer. - Multisectoral Collaboration: Effective AMR management requires coordination across human health, animal agriculture, environmental protection, and food systemsâreflecting the interconnected nature of how resistance spreads. - Research and Development: Accelerating the development of novel antibiotics through targeted incentives, regulatory support, and public-private partnerships to close the gap between emerging resistance and available treatments. - Surveillance and Data Sharing: Implementing real-time monitoring systems that track resistance patterns globally and share data transparently to enable rapid response. What Are the Main Challenges Ahead? Despite the agreement's inclusion of AMR, significant obstacles remain. A rapid literature review of 56 studies examining the implications found that only 2 were empirical researchâhighlighting a critical gap in evidence-based data to guide implementation. The analysis identified three major barriers: inequity in access to antibiotics and diagnostics, inadequate governance structures in many countries, and insufficient financing to support the necessary infrastructure changes. "Factors that may impede implementation of the agreement currently outweigh driving forces," the researchers concluded. This sobering assessment underscores that including AMR in the pandemic agreement is a positive first step, but translating that commitment into real-world action will require sustained political will, investment, and coordination across borders and sectors. The pandemic agreement also prompted amendments to the International Health Regulations (IHR), adopted in May 2024, which focus on strengthening national capacities, enhancing multisectoral coordination, improving access to medical products, and securing sustainable financing. These changes aim to address systemic weaknesses in global health governance that became apparent during the COVID-19 pandemic. Why Should You Care About Antibiotic Resistance? Antibiotic resistance affects everyone. If bacteria continue to develop resistance faster than new drugs are developed, routine infectionsâfrom urinary tract infections to surgical wound infectionsâcould become untreatable. Healthcare costs will rise, hospital stays will lengthen, and mortality rates for common infections will climb. The inclusion of AMR in the pandemic agreement signals that global leaders recognize this threat and are beginning to act, but the success of these efforts depends on implementation at the national and local levels. The consensus among experts is clear: strengthening governance frameworks, fostering equity, and ensuring fair access to health resources are imperative. The world has the tools and knowledge to address antibiotic resistanceâwhat's needed now is the commitment to use them.
